Cytokinetics Inc
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company in South San Francisco that develops muscle-directed medicines for heart and muscle diseases. Its approved drug, MYQORZO (aficamten), treats obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and works too hard. Founded in 1997 by four scientists, including Stanford's James Spudich, the company grew out of research on myosin, the motor protein that powers muscle contraction. The name "Cytokinetics" blends "cyto" (cell) and "kinetics" (motion), reflecting the founders' original study of how cells move.
3.50% Convertible Senior Notes due July 1, 2027
Bought 1.52M · Sold 1.05M
Sold 431.0K
Bought 500.0K
Bought 342.1K · Sold 1.07M
Granted 2.48M · Sold 1.56M
Sold 59.4K
Granted 1.00M · Sold 669.3K
Granted 364.6K · Sold 109.0K
Bought 60.0K · Sold 1.74M
Granted 107.9K
Granted 180.8K · Sold 65.2K
Granted 169.5K · Bought 6.0K · Sold 95.0K
Granted 142.8K · Sold 70.7K
Granted 338.5K · Sold 268.5K
Granted 267.5K · Sold 143.2K
Granted 529.6K · Sold 699.9K
Granted 30.0K · Sold 15.0K
Granted 137.4K
Granted 153.3K · Sold 118.3K
Granted 151.5K · Sold 21.9K
Granted 139.5K · Sold 117.5K
Granted 31.6K · Sold 28.4K
Granted 33.9K
Granted 33.1K
Granted 70.4K · Sold 41.7K
Granted 99.6K · Sold 67.3K
Granted 81.0K · Bought 31.9K · Sold 77.5K
Granted 32.5K
Granted 31.8K · Sold 5.5K
Granted 29.3K · Sold 7.5K
Granted 20.0K
Granted 113.9K · Sold 93.3K
Granted 15.0K
Granted 228.6K · Sold 209.8K
Granted 41.1K · Sold 20.3K
Granted 209.2K · Sold 193.4K
Granted 35.0K
Granted 116.7K · Sold 106.4K
Granted 10.2K
Granted 15.0K · Sold 15.0K
Granted 6.0K
Granted 3.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schmertzler MichaelDirector · 9 transactions | — | 37.20Mas of Jun 2010 | — | 1.52M | 1.05M |
| Biotechnology Value Fund II LP +9 co-filersSee Explanation of Responses, See Explanaton of Responses · 3 transactions | — | 3.81Mas of Dec 2020 | — | — | 431.0K |
| Dart Kenneth Bryan +2 co-filers10% owner · 1 transaction | — | 2.88Mas of Feb 2014 | — | 500.0K | — |
| Biotechnology Value Fund II LP +6 co-filersSee Explanation of Responses, 10% owner · 9 transactions | — | 2.35Mas of Feb 2020 | — | 342.1K | 1.07M |
| Blum Robert IPresident & CEO, Director · 563 transactions | — | 389.5K | 2.48M | — | 1.56M |
| Spudich James ADirector · 82 transactions | — | 180.6Kas of May 2011 | — | — | 59.4K |
| Malik Fady IbrahamEVP Research & Development · 273 transactions | — | 157.4K | 1.00M | — | 669.3K |
| Cragg DavidChief HR & Admin Officer · 46 transactions | — | 153.2Kas of Mar 2022 | 364.6K | — | 109.0K |
| Dow Stephen MDirector · 8 transactions | — | 145.0Kas of Nov 2012 | — | 60.0K | 1.74M |
| Hessekiel JeffreyChief Legal & Admin Officer · 2 transactions | — | 107.9K | 107.9K | — | — |
| Schlossberg Mark ASVP - Legal & General Counsel · 18 transactions | — | 98.6Kas of Mar 2022 | 180.8K | — | 65.2K |
| Henderson John TDirector · 64 transactions | — | 78.2K | 169.5K | 6.0K | 95.0K |
| Lee SungEVP, Chief Financial Officer · 27 transactions | — | 65.3K | 142.8K | — | 70.7K |
| Callos AndrewEVP, Chief Commercial Officer · 68 transactions | — | 58.6K | 338.5K | — | 268.5K |
| Jaw ChingSVP Finance & CFO · 38 transactions | — | 57.3Kas of Mar 2023 | 267.5K | — | 143.2K |
| Sabry James HFormer Executive Chairman · 414 transactions | — | 49.5Kas of Jun 2010 | 529.6K | — | 699.9K |
| Trautman Jay KVP, Discovery Research · 18 transactions | — | 48.8Kas of Mar 2008 | 30.0K | — | 15.0K |
| Barbari Sharon SurreyEVP, Finance & CFO · 7 transactions | — | 47.6Kas of Feb 2017 | 137.4K | — | — |
| Morgan Bradley PaulSVP Drug Discovery & Early Dev · 33 transactions | — | 47.5Kas of Aug 2017 | 153.3K | — | 118.3K |
| Wolff Andrew ASVP & CMO · 13 transactions | — | 47.3Kas of Feb 2017 | 151.5K | — | 21.9K |
| Morgans David J JrEVP-Preclinical R&D · 111 transactions | — | 42.0Kas of Mar 2011 | 139.5K | — | 117.5K |
| Wierenga WendellDirector · 10 transactions | — | 35.5K | 31.6K | — | 28.4K |
| Wysenski NancyDirector · 28 transactions | — | 33.9K | 33.9K | — | — |
| Pletcher Brett AEVP, Chief Legal Officer · 1 transaction | — | 33.1Kas of Aug 2024 | 33.1K | — | — |
| McDowell Caryn GordonGC & Chief Compliance Officer · 88 transactions | — | 32.5Kas of Feb 2018 | 70.4K | — | 41.7K |
| Wierenga WendallDirector · 48 transactions | — | 32.3Kas of Jul 2025 | 99.6K | — | 67.3K |
| Gage L PatrickDirector · 56 transactions | — | 30.8Kas of Nov 2021 | 81.0K | 31.9K | 77.5K |
| Schnieders ElisabethSr. VP, Business Development · 3 transactions | — | 29.0Kas of Feb 2017 | 32.5K | — | — |
| Bhanji MunaDirector · 13 transactions | — | 26.4K | 31.8K | — | 5.5K |
| Harrington Robert ArthurDirector · 24 transactions | — | 21.8K | 29.3K | — | 7.5K |
| Roddy Peter SSVP Finance & CAO · 1 transaction | — | 21.5Kas of Feb 2018 | 20.0K | — | — |
| Costa Santo JDirector · 24 transactions | — | 20.6Kas of May 2024 | 113.9K | — | 93.3K |
| Rabson MichaelSVP Business Dev/Legal & GC · 1 transaction | — | 20.0Kas of Dec 2009 | 15.0K | — | — |
| Smith Sandford DDirector · 89 transactions | — | 18.8Kas of Jan 2024 | 228.6K | — | 209.8K |
| Wong RobertVP, Chief Accounting Officer · 22 transactions | — | 17.9Kas of Dec 2024 | 41.1K | — | 20.3K |
| Parshall B LynneDirector · 53 transactions | — | 15.8K | 209.2K | — | 193.4K |
| Charpentier BonnieSVP Regulatory & Compliance · 3 transactions | — | 15.0Kas of Feb 2017 | 35.0K | — | — |
| Kaye Edward M. MDDirector · 44 transactions | — | 10.3K | 116.7K | — | 106.4K |
| Landry Robert EDirector · 2 transactions | — | 10.2K | 10.2K | — | — |
| Mr. CostaDirector · 3 transactions | — | 10.0Kas of Sep 2022 | 15.0K | — | 15.0K |
| Califf RobertDirector · 7 transactions | — | 6.0Kas of Jan 2022 | 6.0K | — | — |
| Daly James MDirector · 3 transactions | — | 3.2K | 3.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -6.71M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.